The History of Contrast Media Development in X-Ray Diagnostic Radiology
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Introduction to Neuroimaging
Introduction to Neuroimaging Aaron S. Field, MD, PhD Assistant Professor of Radiology Neuroradiology Section University of Wisconsin–Madison Updated 7/17/07 Neuroimaging Modalities Radiography (X-Ray) Magnetic Resonance (MR) Fluoroscopy (guided procedures) • MR Angiography/Venography (MRA/MRV) • Angiography • Diffusion and Diffusion Tensor • Diagnostic MR • Interventional • Perfusion MR • Myelography • MR Spectroscopy (MRS) Ultrasound (US) • Functional MR (fMRI) • Gray-Scale Nuclear Medicine ―Duplex‖ • Color Doppler • Single Photon Emission Computed Tomography (SPECT) Computed Tomography (CT) • Positron Emission Tomography • CT Angiography (CTA) (PET) • Perfusion CT • CT Myelography Radiography (X-Ray) Radiography (X-Ray) Primarily used for spine: • Trauma • Degenerative Dz • Post-op Fluoroscopy (Real-Time X-Ray) Fluoro-guided procedures: • Angiography • Myelography Fluoroscopy (Real-Time X-Ray) Fluoroscopy (Real-Time X-Ray) Digital Subtraction Angiography Fluoroscopy (Real-Time X-Ray) Digital Subtraction Angiography Digital Subtraction Angiography Indications: • Aneurysms, vascular malformations and fistulae • Vessel stenosis, thrombosis, dissection, pseudoaneurysm • Stenting, embolization, thrombolysis (mechanical and pharmacologic) Advantages: • Ability to intervene • Time-resolved blood flow dynamics (arterial, capillary, venous phases) • High spatial and temporal resolution Disadvantages: • Invasive, risk of vascular injury and stroke • Iodinated contrast and ionizing radiation Fluoroscopy (Real-Time X-Ray) Myelography Lumbar or -
Myelography in the Assessment of Degenerative Lumbar Scoliosis And
https://doi.org/10.14245/kjs.2017.14.4.133 KJS Print ISSN 1738-2262 On-line ISSN 2093-6729 CLINICAL ARTICLE Korean J Spine 14(4):133-138, 2017 www.e-kjs.org Myelography in the Assessment of Degenerative Lumbar Scoliosis and Its Influence on Surgical Management George McKay, Objective: Myelography has been shown to highlight foraminal and lateral recess stenosis more Peter Alexander Torrie, readily than computed tomography (CT) or magnetic resonance imaging (MRI). It also has the Wendy Bertram, advantage of providing dynamic assessment of stenosis in the loaded spine. The advent of weight-bearing MRI may go some way towards improving assessment of the loaded spine Priyan Landham, and is less invasive, however availability remains limited. This study evaluates the potential Stephen Morris, role of myelography and its impact upon surgical decision making. John Hutchinson, Methods: Of 270 patients undergoing myelography during 2006-2009, a period representing Roland Watura, peak utilisation of this imaging modality in our unit, we identified 21 patients with degenerative Ian Harding scoliosis who fulfilled our inclusion criteria. An operative plan was formulated by our senior author based initially on interpretation of an MRI scan. Subsequent myelogram and CT myelogram Department of Spinal Surgery, investigations were scrutinised, with any additional abnormalities noted and whether these im- Southmead Hospital, Bristol, United pacted upon the operative plan. Kingdom Results: From our 21 patients, 18 (85.7%) had myelographic findings not identified on MRI. Of Corresponding Author: note, in 4 patients, supine CT myelography yielded additional information when compared to George McKay supine MRI in the same patients. -
Central Venous Access with Accelerated Seldinger Technique Versus Modified Seldinger Technique
Central Venous Access with Accelerated Seldinger Technique versus Modified Seldinger Technique L A N E THAUT , D O , CAPT , M C , USAF SAN ANTONIO MILITARY MEDICAL CENTER CO- AUTHORS: WELLS WEYMOUTH, MD, DANIEL RESCHKE, MD, BRANDEN HUNSAKER,MD Disclosures Expired POWERWAND™ combination device kits were donated by Access Scientific for the express purpose to be used in this study; however, no other contributions were made. We approached Access Scientific to obtain the devices to conduct this study. No financial relationship with Access Scientific. Background Techniques Research and Outcomes Questions Background Air Force SAMMC San Antonio, TX Level 1 Trauma Center 85,000+ patients annually Central Access Common Procedure Approximately 8% of hospitalized patients Multiple indications Large volume fluid or blood product resuscitation Administration of central acting medications Multiple medications simultaneously Trans venous pacing Difficult peripheral access Quick Story What if there was a simpler/quicker way? Intra-osseous? Complications Slower Flow Rate Labs Traditional Central Line Multiple steps/parts Midlines Usually used for extended dwelling lines. Self contained, all in one device. Equivalent and sometimes superior flow rate. Question Will the use of combination devices (midline/POWERWAND™) and the associated accelerated technique reduce the time of CVC placement? VS What is Accelerated Seldinger Technique? Needle, guidewire, dilator, and sheath into one. The device needle is inserted into the target vein under ultrasound guidance and a flash is observed The internal guidewire is then advanced into the vein and snapped into the needle hub. Dilator collar is turned and the dilator and sheath are advanced The dilator hub is disengaged from the needle hub, and the guidewire, dilator, and needle are all removed as a single unit. -
Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4 -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate. -
Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming. -
ICD~10~PCS Complete Code Set Procedural Coding System Sample
ICD~10~PCS Complete Code Set Procedural Coding System Sample Table.of.Contents Preface....................................................................................00 Mouth and Throat ............................................................................. 00 Introducton...........................................................................00 Gastrointestinal System .................................................................. 00 Hepatobiliary System and Pancreas ........................................... 00 What is ICD-10-PCS? ........................................................................ 00 Endocrine System ............................................................................. 00 ICD-10-PCS Code Structure ........................................................... 00 Skin and Breast .................................................................................. 00 ICD-10-PCS Design ........................................................................... 00 Subcutaneous Tissue and Fascia ................................................. 00 ICD-10-PCS Additional Characteristics ...................................... 00 Muscles ................................................................................................. 00 ICD-10-PCS Applications ................................................................ 00 Tendons ................................................................................................ 00 Understandng.Root.Operatons..........................................00 -
Practice Parameter for the Use of Ultrasound to Guide Vascular Access Procedures
PRACTICE GUIDELINES AIUM Practice Parameter for the Use of Ultrasound to Guide Vascular Access Procedures I. Introduction he clinical aspects of this parameter were developed collaboratively among the AIUM and other organizations whose members use ultrasound for guidance in vascular T “ ” access procedures (see Acknowledgments ). Recommendations for practitioner requirements, the written request for the examination, procedure documentation, and quality control vary among the organizations and are addressed by each separately. This parameter has been developed by and for clinicians from diverse specialties and practitioner levels who perform vascular access. While vascular access may be performed using external landmarks, point-of-care ultrasound is now increasingly available.1 Appropriately used, ultrasound guidance for vascular access has been shown to improve success rates while reducing iatrogenic injury, the number of needle passes, and infection rates.2 Addition- ally, it may improve patient comfort and satisfaction. This parameter is intended to be evidence based when possi- ble and to include selected references of importance, but it is not meant to be a comprehensive or rigorous literature review, as this has been accomplished elsewhere.3 The intent of this document is to highlight appropriate evidence while also providing a practical, real-world expert consensus from clinicians with diverse back- grounds on the best use and techniques for incorporating ultra- sound into vascular access procedures with the ultimate goal of improving the care of our patients. II. Indications/Contraindications Ultrasound should be used to aid in central venous, peripheral venous, and arterial access procedures.4 When used appropriately by qualified personnel, there are no absolute contraindications to using ultrasound as a procedural adjunct for vascular guidance. -
Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object. -
Assessment of Bronchiectasis by Computed Tomography
Thorax: first published as 10.1136/thx.40.12.920 on 1 December 1985. Downloaded from Thorax 1985;40:920-924 Assessment of bronchiectasis by computed tomography IM MOOTOOSAMY, RH REZNEK, J OSMAN, RSO REES, MALCOLM GREEN From the Departments of Diagnostic Radiology and Chest Medicine, St Bartholomew's Hospital, London ABSTRACT Computed tomography and bronchography were used to assess the distribution of bronchiectasis in 15 lungs from eight patients with clinical features of the disease. Of the 36 lobes adequately displayed by bronchography, 22 were found to have bronchiectasis and 14 were found to be normal by both techniques. Cystic disease was readily identified by computed tomography but the cylindrical and varicose types of bronchiectasis could not be distinguished. Segmental local- isation was less accurate, with agreement between computed tomography and bronchography in 116 out of 130 segments. It is concluded that with a modern high resolution scanner computed tom- ography provides a useful method of assessing lobar distribution in bronchiectasis. The incidence of bronchiectasis in the United King- placing bronchography in a substantial number, dom has decreased since the advent ofantibiotic treat- Muller et al found correspondence in only about half ment and the decline in severe respiratory disease in the lungs studied. childhood. Nevertheless, it still occurs as the result of The purpose of this study is to assess the place of severe pulmonary infections and in association with modern high resolution computed tomography scan-copyright. immune deficiency, cystic fibrosis, and other condi- ners in the clinical management ofpatients with bron- tions. chiectasis and to investigate the accuracy with which The disease is defined as irreversible abnormal di- lobar and segmental disease and the type of disease latation of the bronchi and has been classified by present can be predicted. -
Page 1 Note: Within Nine Months from the Publication of the Mention
Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.